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Increased risk of second cancers at sites associated with HPV
after a prior HPV-associated malignancy, a systematic review
and meta-analysis
Duncan C. Gilbert1,2, Katie Wakeham2, Ruth E. Langley1 and Claire L. Vale1
BACKGROUND: High-risk human papilloma viruses (HPV) are a causative agent of anogenital and oropharyngeal cancers. Patients
treated for a preinvasive or invasive HPV-associated cancer may be at increased risk of a second such malignancy.
METHODS:We performed a systematic review and random effects meta-analysis to estimate the risk of HPV-associated cancer after
prior diagnosis. Studies reporting second cancers at anogenital and oropharyngeal sites after prior diagnoses (preinvasive/invasive
HPV-associated cancer) were identiﬁed. Studies reporting standardised incidence ratios (SIRs) were included in formal meta-
analyses of second cancer risk. (PROSPERO ID: CRD42016046974).
RESULTS: Searches returned 5599 titles, including 60 unique, eligible studies. Thirty-two (98 comparisons) presented SIRs for
second cervical, anal, vulvo-vaginal, penile, and/or oropharyngeal cancers, included in the meta-analyses. All studies (and 95/98
comparisons) reported increased cancers in the population with previous HPV-associated cancer when compared to controls.
Pooled SIRs for second primary cancers ranged from 1.75 (95% CI 0.66−4.67) for cervical cancer after primary anal cancer, to 13.69
(95% CI 8.56−21.89) for anal cancer after primary vulvo-vaginal cancer.
CONCLUSIONS: We have quantiﬁed the increased risk of second HPV-associated cancer following diagnosis and treatment for
initial cancer or preinvasive disease. This has important implications for follow-up, screening, and future therapeutic trials.
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BACKGROUND
High-risk human papilloma viruses (HPV) are acknowledged as
causing cancers of the cervix, anus, vulva, vagina, penis and
oropharynx. The incidence of HPV-associated anogenital and
oropharyngeal cancers is rising in the developed world and is a
major cause of morbidity and mortality across low and middle-
income countries. Approximately 5% of all cancers worldwide are
caused by HPV1 with the proportion of cancers attributable to HPV at
each site ranging from 50% (vulval) to ~90% (anal).2 Cancers arising at
these sites have marked biological similarities3 and treatment
protocols. Many HPV-associated cancers and precancerous lesions
(termed intraepithelial neoplasia) present with early disease and cure
rates following surgical excision (i.e. for early-stage cervical cancers or
anal intraepithelial neoplasia) are excellent.4,5 For patients with locally
advanced disease (for example head and neck or anal squamous cell
carcinomas) treatment typically involves radical chemo-radiotherapy,
with relatively high rates of long-term survival.6,7
Although patients diagnosed with primary HPV-associated
cancers then are often cured, they remain at risk of second HPV-
associated malignancies. A number of factors likely contribute to
this increased risk including prior exposure to high-risk subtypes
of HPV where sexual behaviour promulgates this risk.8 Intra-
patient transmission of HPV across the various anatomical sub
sites of the anogenital regions is recognised. Additionally, there is
evidence to support underlying biological susceptibility to HPV-
associated cancers where candidate gene approaches or genome-
wide association studies suggest that polymorphisms within
immune pathways might play a role. Variants of the TGF beta
receptor 1 have been associated with HPV-associated head and
neck cancer 9 and MHC variants linked with cervical cancer.10 A
number of registry and other studies report incidence rates of
second primary HPV-associated cancer, typically focussing on a
single primary tumour and a subset of the potential second
cancers. However, a more accurate estimate of this risk is required
following treatment of the initial cancer to understand the need
for and inform the design of follow-up and surveillance protocols.
It would also facilitate the investigation of additional treatments in
the future such as novel screening or therapeutic vaccination
strategies to reduce the risk of second cancers.
We therefore conducted a systematic literature review and
meta-analysis to estimate the overall rates of second HPV-
associated cancers following treatment of an initial such tumour.
METHODS
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Study eligibility
Systematic review. To be comprehensive, studies were consid-
ered eligible for inclusion in the systematic review if they reported
second HPV-associated cancers after an initial index cancer (or
preinvasive, in situ neoplasia) at a site associated with HPV
infection, i.e. invasive cervical, vaginal, vulval, anal, or penile
cancers or their associated preinvasive lesions (CIN/VAIN/VIN/AIN/
PIN) or cancers of the oropharynx (tonsil and tongue base). These
included previous systematic reviews, cohort studies including
from cancer registries, and phase III trials of radical treatment that
report second cancers. All eligible studies were included in the
results of the systematic review.
Meta-analysis. To limit ascertainment bias, only studies that
measured and reported the same statistics using the same
measures were included in the formal meta-analysis. Studies
reporting the risk of second cancers in a population affected by
the primary index cancer compared with the risk of those cancers
in a contemporary control population not affected by the primary
cancer (e.g. derived from SEER data) were eligible for inclusion in
the meta-analysis. Speciﬁcally, this must have been presented as a
standardised incidence ratio (SIR), calculated by dividing the
observed incidence of second primary malignancies (SPM) by the
incidence for the general population, measured from the rest of
the registry unaffected by the primary cancer in question.11
Study identiﬁcation
To identify eligible studies that reported subsequent incidences of
cancers including, but not limited to, those known to be
associated with HPV after an initial diagnosis, we developed a
comprehensive search strategy for MEDLINE. The search strategy
included MeSH and free-text terms for each of the HPV-associated
cancer sites or precancerous in situ disease states, namely cervix,
vagina, vulva, oropharynx, penis and anus, as well as for each of
the relevant study types and for second primary cancer. The
strategy used is given in Appendix 1 (supplementary material).
Web of Science, ASCO, ESMO/ECCO databases and conference
proceedings of the International Papillomavirus Society (IPVS)
were also searched for relevant articles or abstracts. Reference lists
of included articles were manually screened to retrieve any
additional eligible studies. Searches were updated until 7 July
2016.
Data extraction
Data were extracted from the reports of all studies identiﬁed as
being eligible for inclusion in the systematic review using a
predeﬁned form, including where available: origin of patient
population (registry, single centre cohort, randomised trial cohort);
time points of initial diagnosis; number at risk; subsequent
incidence of HPV-associated cancers and precancerous in situ
disease of the anogenital region (cervical, vulval, vaginal, penile,
anal) and the oropharynx (speciﬁcally, base of tongue and tonsil).
In addition, for studies to be included in the formal meta-analysis,
SIR and associated statistics for each second primary HPV-
associated cancer were also extracted.
Risk of bias/quality assessment of studies
Since all eligible studies were of cohort design, the
Newcastle–Ottawa quality assessment scale12 was used to
evaluate methodological quality. A meta-analysis of observational
studies in epidemiology (MOOSE) checklist 13 was completed and
is included in the Supplementary Materials.
Statistical analysis
Absolute numbers of second cancers and associated standardised
incidence rates (SIR)11 were tabulated from each study, organised
according to the site of index primaries. Where SIR for relevant
individual sites of second primary cancer (vulval and vaginal
cancers or tonsil and tongue base) were reported separately, data
were pooled using a random effect meta-analysis to obtain a
single SIR for the combined site (i.e. vulvo-vaginal and
oropharyngeal).
For each second cancer type (cervix, anal, oropharynx, penile
and vulvo-vaginal) the SIRs and associated statistics from the
individual studies were combined in a formal meta-analysis
according to the index cancer site, to obtain an estimate of the
risk of independent second primary cancer following individual
index primaries. Chi-square tests for interaction were used to
investigate whether there were any substantial differences in the
risk of second primary cancers between groups of studies based
on primary cancer type. SIRs and associated statistics for second
primary cancer at the same location as the index HPV-associated
cancer were considered separately.
Statistical heterogeneity and inconsistency14 were also assessed
within the subgroups of studies based on the index HPV-
associated cancer for each second primary cancer type. To
account for expected heterogeneity between studies, a random
effects meta-analysis model was used.15 Analyses were conducted
using the IPDmetan command16 in Stata version 14.
RESULTS
Eligible studies
Searches returned 5599 titles, which were screened for eligibility
(Fig. 1). Sixty studies fulﬁlled the criteria for the systematic review;
5599 unique articles identified from
searches
259 abstracts screened for eligibility
criteria
5340 articles excluded after
screening of title
99 full text articles assessing
incidence of HPV associated
tumours after initial diagnosis
160 articles excluded after
screening of abstract
32 studies included in meta-analysis
39 articles excluded after
assessment of full paper,
including for overlapping data
18 articles reported absolute
numbers of second cancer cases
without contemporary controls*
10 articles reported SIR without
confidence intervals#
60 eligible studies
Fig. 1 PRISMA ﬂow diagram of identiﬁcation and selection of
eligible studies. *Included in discussion with respect to estimation of
absolute risk of subsequent HPV-associated cancer, Table S1.
#Included in Table S2
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however, 18 studies17–32 reported institutional cohorts with
absolute numbers of second primaries (Table S1) and a further
10 studies33–42 reported second primaries and SIRs without
providing either conﬁdence intervals or standard errors (Table S2),
so they could not be included in the formal meta-analyses. The
remaining 32 studies43–74 from large institutional, regional or
national cancer registries (representing 16 countries), all reported
SIRs and associated statistics and are therefore included in the
meta-analysis (two pairs of studies reported overlapping data from
the same sources and were combined). These 32 studies
comprised 3,759,726 patients and yielded 98 comparisons of
individual sites of HPV-associated cancer after an index case.
Characteristics of the 32 studies are shown in Table 1. All
32 studies were assessed as having reasonable quality (score
range: 5−8) according to the Newcastle Ottawa framework. A
MOOSE checklist13 is included in the supplementary materials.
Anal cancer after a primary HPV-associated cancer or preinvasive
tumour
Two studies (two comparisons)51,66 reported incidence of second
primary anal cancer following the same index cancer. Figure 2
shows that the combined SIR for these two studies was 30.81 (95%
CI 23.5−40.39) and no evidence of heterogeneity or inconsistency
between the studies (p= 0.697, I2= 0).
Fourteen studies (28 comparisons)44,47,48,51,54,58,62 reported
rates of second primary anal cancer after an initial diagnosis of
an independent index HPV-associated cancer. While there is
considerable heterogeneity between studies grouped by primary
cervical (heterogeneity p < 0.001; I2 91.5%), CIN (heterogeneity p <
0.001; I2 96.36%) and vulvo-vaginal (heterogeneity p= 0.018; I2
63.4%) cancers, and also evidence of signiﬁcant variation between
groups (test for interaction p < 0.001), the tendency towards an
increase in risk is observed for all studies, and across each of the
index sites. SIRs for individual index tumours ranged from 2.70
(95% CI 1.17−6.23) following an oropharyngeal index tumour to
13.69 (95% CI 8.56−21.89) after vulvo-vaginal index tumours
(Fig. 3a and Table 1).
Cervical cancer after a primary HPV-associated cancer or
preinvasive tumour
Two studies (two comparisons)49,51 reported incidence of second
primary cervical cancer following a primary cervix cancer. Figure 2
shows that the combined SIR for these two studies was 1.61 (95%
CI 0.39−6.65) although there is evidence of heterogeneity and
inconsistency between the studies (p= 0.005, I2= 87.5%). Thir-
teen studies (17 comparisons)43,48,51–53,55,57,59,63,65,73 reported
second primary cervical cancers after an independent primary
HPV-associated cancer. While there is considerable heterogeneity
between studies grouped by CIN (heterogeneity p= 0.016; I2
59.3%) and vulvo-vaginal (heterogeneity p= 0.017; I2 75.3%) index
cancers, there is no evidence of variation in risk between groups
(test for interaction p= 0.514). SIRs ranged from 1.75 (95% CI 0.66
−4.67) following primary anal cancer to 5.95 (95% CI 1.39−25.47)
following vulvo-vaginal cancer (Fig. 3b and Table 1).
Vulvo-vaginal cancer after a primary HPV-associated cancer or
preinvasive tumour
Two studies (two comparisons)51,57 reported incidence of second
primary vulvo-vaginal cancer following the same index HAC.
Figure 2 shows that the combined SIR for these two studies was
9.08 (95% CI 5.46−15.12) with no evidence of heterogeneity
between the studies (p= 0.492, I2= 0). Nineteen studies with 24
comparisons43,44,47,54,57,58,60,63,65,66 reported second primary
vulvo-vaginal cancer (Fig. 3c). There is considerable heterogeneity
and inconsistency between studies grouped by cervical (hetero-
geneity p < 0.001; I2 90.8%) and CIN (heterogeneity p= 0.001; I2
68.8%) index cancers, and evidence of variation in risk between
index cancer groups (test for interaction p= 0.001). However, an
increase in risk is observed for all except three of the individual
studies and to each of the index sites. The SIRs for individual index
tumours ranged from 3.74 (95% CI 1.72−8.15) for oropharyngeal
index tumours to 9.13 (95% CI 5.84−14.28) for index anal cancers
(Fig. 3c and Table 1).
Oropharyngeal cancer after a primary HPV-associated cancer or
preinvasive tumour
Eight studies (ten comparisons)51,52,58,68,69,71,74 reported incidence of
second primary oropharyngeal cancers following a cancer at the
same location. Figure 2 shows that the combined SIR for these
studies was 22.45 (95% CI 12.70−39.68) with substantial evidence of
heterogeneity between the studies (p < 0.001, I2= 98%). Twelve
studies (19 comparisons)43,44,47,48,51,52,56,57,60,64,67 reported second
primary oropharyngeal cancer. There is considerable heterogeneity
and inconsistency between studies grouped by cervical (hetero-
geneity p= 0.042; I2 54.2%) and CIN (heterogeneity p < 0.001; I2
86.9%) and anal (heterogeneity p= 0.024; I2 64.3%) index cancers,
and evidence of variation in risk between index cancer groups (test
for interaction p < 0.001). However, a tendency towards an increase
in risk is observed for the majority of individual studies, and for each
of the index sites. The SIR for individual index tumours ranged from
1.72 (95% CI 1.36−2.19) for cervical index tumours to 4.87 (95% CI
1.96−12.08) for anal index tumours (Fig. 3d and Table 1). As cancers
of the tonsil or tongue base are speciﬁc oropharyngeal tumours
strongly related to the presence of HPV, we carried out a sensitivity
analysis in which we limited the meta-analysis to the six studies that
speciﬁcally reported incidence rates of second primary cancers at
these sites.43,44,56,60,64,67 While there is less power overall, the
magnitude and direction of the risks were similar to those obtained
for any second cancer of the oropharynx (Figure S1, Supplementary
material).
Penile cancer after a primary HPV-associated cancer
Just three studies65–67 representing only nine cases reported
second primary penile cancer, with SIRs ranging from 0.9 (0.0−4.7)
to 2.93 (0.07−16.33). Formal meta-analysis was deemed
inappropriate.
DISCUSSION
We have demonstrated that for patients diagnosed with HPV-
associated invasive or preinvasive tumours, the risk of a second
HPV-associated cancer at most sites is approximately a ﬁvefold
increase as compared with unaffected individuals; although for
subsequent cervical cancers, this increase in risk is somewhat less
(around 2-fold). There appears to be a particularly strong link
between anal and vulvo-vaginal cancers, where either diagnosis
confers around a tenfold increased risk of a second cancer at the
other site. There is also a high rate of second cancers observed at
the same anatomical site (acknowledging that it is difﬁcult to
differentiate recurrences from true second primary cancers from
registry data in this context). For individuals this increased risk is
likely to arise as a combination of exposure to high-risk HPV
subtypes (so mediated by sexual behaviour) and subsequent inter-
and intra-site transmission of HPV within individuals, and
potentially host susceptibility where it has been suggested that
mediators of immune clearance of HPV might play a role.9,10
Ours is the ﬁrst systematic review and meta-analysis to have
estimated the risk of developing a second primary HPV-associated
cancer encompassing all anogenital and oropharyngeal sites. We
have included data from 32 studies representing patients from 14
countries and spanning 77 years. Anticipating heterogeneity
between the studies, we planned our analyses accordingly, using
a random effects model to complete the meta-analysis, grouping
studies according to the index primary cancer site. We also
excluded studies that did not use a contemporaneous control
from the meta-analysis as we felt that studies reporting SIRs were
Increased risk of second cancers at sites associated with HPV after a. . .
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more reliable in terms of methodological quality. Application of
the SIRs produced by this approach to current incidence rates75
(Table 2) gives estimates that are an order of magnitude less than
those seen in studies reporting an institutional cohort of index
cancers (Table S1). However, as patients included in these
institutional cohort studies are likely to have been selected, and
potentially followed up more intensely after primary treatment,
they are more likely to have diagnosed early lesions than would
be expected through a cancer registry approach. Hence, although
the registry data gives a potentially more conservative estimate of
second cancer risk, it is also likely to be more reliable and
representative.
Misclassiﬁcation of tumours in registry-based studies may
introduce over- or underestimation of second cancer incidence
rates. For example, differentiating between true second cancers
and local recurrences (and how this pertains to progression of
preinvasive disease) in practice can be difﬁcult, and lead to
classiﬁcation of local recurrences as second primary lesions. Some
of the included studies reported attempts to account for this,
notably by excluding second cancers at the same anatomical site
that were identiﬁed within the ﬁrst year after diagnosis (Table 1).
In our meta-analyses, we have presented the rates of subsequent
disease at the same site separately to try and avoid any
overestimate of risk due to inclusion of local recurrences. Another
opportunity for misclassiﬁcation may arise due to the close
anatomical proximity of anogenital cancers. Registry data might
record a local recurrence that invades an adjacent organ as a
second primary cancer. However, results from institutional series
(that might be expected to suffer less from these problems—
supplementary material Table S1) report higher rates of second
cancers suggesting this issue has not signiﬁcantly inﬂated the SIRs
seen from the registries. Finally, difﬁculties in discriminating
tumours arising in discrete sites within the oropharynx may have
led to some misclassiﬁcations and as we cannot be completely
conﬁdent of tumour classiﬁcations reported within the registry
studies, there may be some over- or underestimation of risk that
may have occurred in the individual studies. However, the results
of our planned analysis based on risk of oropharynx cancers as
reported, and our sensitivity analysis looking at risk of only tongue
base or tonsil cancers are broadly in keeping with one another,
thus suggesting our interpretation is robust to this.
Although we anticipated that heterogeneity might be an issue
and attempted to address it in our preplanned analyses, by
grouping studies according to initial and second primary cancers,
statistical heterogeneity is still substantial. This is likely to be due
to epidemiological differences between the studies, for example
different extents of follow-up times, the range of time periods
covered by the studies, changing demographics of cancers over
time, different selection criteria for patients and differences in
treatment regimes. Moderate to high heterogeneity has also been
observed in other meta-analyses of second cancer data across a
range of settings,76 with similar reasoning. In addition, as
discussed above, over-or underestimation of second primary
cancers due to difﬁculties in accurate classiﬁcation within registry
studies may also inﬂate the heterogeneity observed between the
study results. However, almost all studies irrespective of the type
and location of tumours show increases in risk of second cancer
following initial primary cancer. The direction of the effect is
broadly consistent, with the vast majority of studies indicating
increased level of risk. The heterogeneity observed in these meta-
analyses arises largely therefore due to differences in the
magnitude of risk observed between studies. Therefore, while
we cannot be certain of the true size of the risk, our results are
indicative of an increase in risk for all of the sites assessed.
Another potential limitation is that data from studies with cervix
as the primary site (whether preinvasive or invasive) predominate,
given their relative incidence. It does mean that the majority of
data included in our analyses are from female patients.
Conversely, due to sparsity of available data, we have not been
able to draw ﬁrm conclusions about the risk of second penile
cancers, beyond the observation that an increased risk is
consistent with the other sites of second HPV-associated tumours.
The registry data that underpins our meta-analysis were
predominately derived from countries with cervical screening
programmes. Effective screening routinely identiﬁes individuals
with precancerous conditions and thus reduces the subsequent
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Fig. 2 Standardised incidence ratios of second primary cancer after HPV-associated primary tumours at the same location
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risk of invasive disease. This may at least in part explain the
smaller increase in risk seen for secondary cervix cancers
compared to other sites. Equally hysterectomy might form part
of the treatment of the initial HPV-associated cancer and as such
further contribute to the lower risk of subsequent cervical cancer
seen. Importantly though, cervical cancer and other HPV-
associated cancers are particularly common in low and middle-
income countries where screening programmes are not well
established. Indeed, there is currently no coordinated surveillance
after a diagnosis of a HPV-associated noncervical cancer for any
population group, raising the concern that early diagnosis of
curable cancer may be missed. Conversely, screening programmes
(through over diagnosis) will expose patients to a range of
detrimental side effects, for example in the treatment of AIN
where a number of approaches are possible,77 and require
prospective evaluation. This is currently being undertaken in the
context of men who have sex with men (MSM) and anal cancer in
the SPANC trial (study for the prevention of anal cancer).78 It
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Fig. 3 a Standardised incidence ratios of anal cancer after HPV-associated primary tumours. b Standardised incidence ratios of cervical cancer
after HPV-associated primary tumours. c Standardised incidence ratios of vulvo-vaginal cancer after HPV-associated primary tumours.
d Standardised incidence ratios of oropharyngeal cancer after HPV-associated primary tumours
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should be noted that none of the studies included in the meta-
analyses contained data on behavioural risk factors such as sexual
behaviour, MSM etc. though it is likely that this will further
modulate risk.
Based on our results, the diagnosis and treatment of index
cancers presents an opportunity for secondary prevention, even
when primary vaccination or screening is lacking. There could be
the potential for therapeutic intervention using novel approaches
in these patients to clear latent HPV infection or eradicate
transformed cells. There is no evidence that the current
prophylactic vaccines can eliminate transformed cells, though
some data show that vaccination of subjects treated for HPV-
associated precancers reduces the risk of new lesions in the
genital tract. A small, nonrandomised cohort study of 202
patients with high-grade AIN79 showed fewer subsequent
diagnoses at 2 years (HR 0.50; 95% CI, 0.26–0.98; p= 0.05)
following quadrivalent HPV vaccination. A separate study80 of 737
patients with CIN2/3, treated with LEEP, also showed reduced
rates of subsequent lesions in patients who subsequently
received the quadrivalent HPV vaccine compared with a
nonvaccinated group. Furthermore, retrospective analysis of data
from randomised controlled trials of the HPV vaccine suggest that
patients who developed a cervical lesion despite vaccination, and
so were likely to have been infected with HPV prior to
vaccination, were still relatively protected from subsequent
recurrent/secondary HPV disease.81 There is also considerable
interest in the development of therapeutic vaccines that
stimulate an immune response against established infection.
Pilot studies of such approaches suggest efﬁcacy in CIN82 and
larger trials including as adjuvant therapy after curative treatment
of invasive cancers are in development. Finally, the growing ﬁeld
of immuno-oncology offers a number of approaches (for example
immune checkpoint inhibitors) that might be utilised to eradicate
HPV transformed cells, whether in reducing local recurrences or
the development of second cancers.
In summary, there is a consistently raised incidence of each of
the HPV-associated tumours as a second cancer after any such
primary. Diagnosis and treatment of these index cancers presents
a unique opportunity for the prevention of subsequent primary
cancers. These data should inform patients and carers alike with
respect to survivorship programmes. They also support new
studies aimed at reducing the risks, whether through targeted
screening of affected individuals, or trials of therapeutic
approaches.
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